tert-butyl ((3R,4aR,7aS,9aR,11S,13aR,13bS,15aS,15bR)-11-methoxy-4,4,7a,10,10,13a,15b-heptamethyl-2,3,4,4a,5,7,7a,8,9,9a,10,11,12,13,13a,13b,14,15,15a,15b-icosahydro-1H-cyclohepta[1,2-a:5,4-a']dinaphthalen-3-yl) malonate | 1186389-79-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: tert-butyl ((3R,4aR,7aS,9aR,11S,13aR,13bS,15aS,15bR)-11-methoxy-4,4,7a,10,10,13a,15b-heptamethyl-2,3,4,4a,5,7,7a,8,9,9a,10,11,12,13,13a,13b,14,15,15a,15b-icosahydro-1H-cyclohepta[1,2-a:5,4-a']dinaphthalen-3-yl) malonate
• CAS: 1186389-79-6
• 化学式: C₃₈H₆₂O₅
• 分子量: 598.907
• InChiKey: OLVAAOJPAOUXEY-FLYXLQIKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.08
• 重原子数：
  43.0
• 可旋转键数：
  4.0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  61.83
• 氢给体数：
  0.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  tert-butyl ((3R,4aR,7aS,9aR,11S,13aR,13bS,15aS,15bR)-11-methoxy-4,4,7a,10,10,13a,15b-heptamethyl-2,3,4,4a,5,7,7a,8,9,9a,10,11,12,13,13a,13b,14,15,15a,15b-icosahydro-1H-cyclohepta[1,2-a:5,4-a']dinaphthalen-3-yl) malonate 在 甲烷磺酸 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以90%的产率得到3-(((3R,4aR,7aS,9aR,11S,13aR,13bS,15aS,15bR)-11-methoxy-4,4,7a,10,10,13a,15b-heptamethyl-2,3,4,4a,5,7,7a,8,9,9a,10,11,12,13,13a,13b,14,15,15a,15b-icosahydro-1H-cyclohepta[1,2-a:5,4-a']dinaphthalen-3-yl)oxy)-3-oxopropanoic acid
  参考文献：
  名称：

  Novel 3α-methoxyserrat-14-en-21β-ol (PJ-1) and 3β-methoxyserrat-14-en-21β-ol (PJ-2)-curcumin, kojic acid, quercetin, and baicalein conjugates as HIV agents

  摘要：

  Sixteen novel compounds; 3 alpha-methoxyserrat-14-en-21 beta-ol (1) and 3 beta-methoxyserrat-14-en-21 beta-ol (2) and their curcumin, kojic acid, quercetin, and baicalein conjugates (3)-(18) were designed, synthesized, and evaluated for in vitro anti-HIV-1 reverse transcriptase (RT) activity in infected C8166-CCR5 cells, a human CD4(+) T-lymphocyte cell line. Among them, kojic acid derivatives, 9-12 showed significant biological activity. In particular, the compound 13, the conjugate of two molecules of 3 alpha-methoxyserrat-14-en-21 beta-ol (1) and one molecule of kojic acid, exerted significant anti-HIV activity with an EC50 value of 0.12 mu g/mL. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.05.049
• 作为产物：
  描述：

  丙二酸单叔丁酯 、 3β-methoxyserrat-14-en-21β-ol 在 4-二甲氨基吡啶 、 N,N-二异丙基乙胺 、 N,N'-羰基二咪唑 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以65%的产率得到tert-butyl ((3R,4aR,7aS,9aR,11S,13aR,13bS,15aS,15bR)-11-methoxy-4,4,7a,10,10,13a,15b-heptamethyl-2,3,4,4a,5,7,7a,8,9,9a,10,11,12,13,13a,13b,14,15,15a,15b-icosahydro-1H-cyclohepta[1,2-a:5,4-a']dinaphthalen-3-yl) malonate
  参考文献：
  名称：

  Novel 3α-methoxyserrat-14-en-21β-ol (PJ-1) and 3β-methoxyserrat-14-en-21β-ol (PJ-2)-curcumin, kojic acid, quercetin, and baicalein conjugates as HIV agents

  摘要：

  Sixteen novel compounds; 3 alpha-methoxyserrat-14-en-21 beta-ol (1) and 3 beta-methoxyserrat-14-en-21 beta-ol (2) and their curcumin, kojic acid, quercetin, and baicalein conjugates (3)-(18) were designed, synthesized, and evaluated for in vitro anti-HIV-1 reverse transcriptase (RT) activity in infected C8166-CCR5 cells, a human CD4(+) T-lymphocyte cell line. Among them, kojic acid derivatives, 9-12 showed significant biological activity. In particular, the compound 13, the conjugate of two molecules of 3 alpha-methoxyserrat-14-en-21 beta-ol (1) and one molecule of kojic acid, exerted significant anti-HIV activity with an EC50 value of 0.12 mu g/mL. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.05.049